Amnestic mild cognitive impairment doubles risk of death

Researchers at Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center have found that people with a form of mild cognitive impairment (MCI), a risk factor for developing Alzheimer's disease, have twice the risk of dying compared with cognitively normal people. Those with dementia have three times the risk. The findings are being presented at the Alzheimer's Association International Conference in Vancouver this week.

Amnestic MCI is a condition in which people have more severe than normal for their age and education, but not serious enough to affect daily life. (Another form of MCI, nonamnestic MCI, is characterized by impaired other than memory, such as trouble planning and organizing or poor judgment.) According to the Alzheimer's Association, long-term studies suggest that 10 to 20 percent of people aged 65 and older may have MCI.

Einstein researchers studied 733 individuals enrolled in the Einstein Aging Study. The participants were at least 70-years-old and lived in The Bronx. At the start of the study, each had a cognitive evaluation for baseline and at least one annual follow-up visit. They were also tested for the APOE-4 , which is linked to increased risk for Alzheimer's. Participants were followed for an average of five years (up to a high of 16 years).

Study investigators found that participants with amnestic MCI had more than two times (2.17) greater risk of death. Nonamnestic MCI did not appear to increase . The risk of death among participants with dementia was more than three times greater (3.26) than that of those who were cognitively normal. Researchers also found that having the APOE-4 gene variant, a greater number of co-morbidities, and were also related to higher risk of mortality.

"While there is no treatment for MCI, dementia or Alzheimer's, these findings support the benefits of early detection and monitoring of cognitive impairment in order to prolong life," said Richard Lipton, M.D., the senior author of the study and director of the Einstein Aging Study. Dr. Lipton is also the Edwin S. Lowe Chair in Neurology at Einstein and professor and vice chair of the Saul R. Korey Department of Neurology at Einstein and Montefiore Medical Center, the University Hospital for Einstein.

The Einstein Aging Study examines both normal brain aging and the special challenges of Alzheimer's disease and other dementias. Since its initial funding 30 years ago by the National Institute on Aging (AG003949), part of the National Institutes of Health, its investigators have contributed to the understanding of brain aging by tracking over 2,000 Bronx County residents in order to facilitate earlier diagnosis, prevention and treatment of Alzheimer's disease.

add to favorites email to friend print save as pdf

Related Stories

Study finds mild cognitive impairment is more common in men

Sep 06, 2010

A new Mayo Clinic study found that the prevalence of mild cognitive impairment was 1.5 times higher in men than in women. The research, part of the Mayo Clinic Study of Aging, also showed a prevalence rate of 16 percent in ...

Study: Men at higher risk for mild memory loss than women

Jan 25, 2012

Men may be at higher risk of experiencing mild cognitive impairment (MCI), or the stage of mild memory loss that occurs between normal aging and dementia, than women, according to a study published in the January 25, 2012, ...

Researchers connect gene to pre-Alzheimer's

Jul 19, 2011

(Medical Xpress) -- Cornell scientists have shown a significant correlation for the first time between a human gene and people's risk for mild cognitive impairment (MCI), often a precursor to Alzheimer's disease and related ...

Recommended for you

New treatment fights common infant virus

5 hours ago

Researchers at Le Bonheur Children's Hospital and the University of Tennessee Health Science Center announced results of a clinical trial of a new drug shown to safely reduce the viral load and clinical illness of healthy ...

User comments